Chloroquine and hydroxychloroquine in covid-19.

Ferner, Robin E; Aronson, Jeffrey K

Ferner, Robin E; Aronson, Jeffrey K.

Ferner RE; Institute of Clinical Sciences, University of Birmingham, Birmingham, UK r.e.ferner@bham.ac.uk.
Aronson JK; Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

BMJ ; 369: m1432, 2020 04 08.

Article in English | MEDLINE | ID: covidwho-20235503

Subject(s)

Antiviral Agents; Betacoronavirus/drug effects; Chloroquine; Coronavirus Infections/drug therapy; Hydroxychloroquine; Pneumonia, Viral/drug therapy; Antiviral Agents/adverse effects; Antiviral Agents/therapeutic use; COVID-19; Chloroquine/adverse effects; Chloroquine/therapeutic use; Clinical Trials as Topic; Drug Evaluation, Preclinical; Endpoint Determination; Humans; Hydroxychloroquine/adverse effects; Hydroxychloroquine/therapeutic use; Pandemics; Research Design; SARS-CoV-2; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Chloroquine / Coronavirus Infections / Betacoronavirus / Hydroxychloroquine Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Humans Language: English Journal: BMJ Journal subject: Medicine Year: 2020 Document Type: Article Affiliation country: Bmj.m1432

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google